Tools to support development of interventions Soili Larkin & Mohammed Vaqar Public Health England West Midlands.

Slides:



Advertisements
Similar presentations
Commissioning for Value 24 th March 2015 Dr Stephen Liversedge NHS Bolton CCG.
Advertisements

Unit 14: Measures of Public Health Impact.
Commissioning to reduce health inequalities: Supporting analysis
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Session 4: Making a case - ROI and business case for tobacco control ARCH Technical Workshop Bali August 2014 Matt Glover Health Economics Research Group.
Evidence into Practice: Diabetes Public Health England May 2014 Dr Junaid Bajwa.
Risk estimation and the prevention of cardiovascular disease SIGN 97.
Improving the Quality of Physical Health Checks
Northern England Strategic Clinical Network Conference 15 th May 2015.
Reducing Inequalities in Primary Care – Where are we? Dr Bobbie Jacobson Director
Using QOF and Service Specifications to meet HI Needs Rachel Foskett-Tharby.
Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
Health equity audit Stuart Harris Public Health Intelligence Analyst Course – Day 4.
Clinical pathway for people with atrial fibrillation or at risk of atrial fibrillation Dr Ruth Chambers OBE LTC Priority Lead, West Midlands Academic Health.
NHS Health Check programme An opportunity to engage 15 million people to live well for longer Louise Cleaver National Programme Support Manager.
TARGETING HIGH RISK GROUPS: LEARNING FROM ISLINGTON AND CAMDEN Kinga Kuczkowska, NHS Health Checks Project Manager Dana Hayes, NHS Health Checks Project.
West Midlands Cardiovascular Strategic Clinical Network and Clinical Senate Rob Wilson CVD Network Manager 26 th February 2015.
THE HEALTH CHALLENGE Sheila Shribman National Clinical Director Children, Young People & Maternity.
Cardiovascular Risk: A global perspective
Health Inequalities. South Tyneside Life Expectancy Gap Life Expectancy – Males Local Value England England England average worst best
Journal Club Curriculum-Study designs. Objectives  Distinguish between the main types of research designs  Randomized control trials  Cohort studies.
Section 1: Introduction Dr Somen Banerjee, Director of Public Health London Borough Tower Hamlets.
AF in the West Midlands: Prevalence, pathways and management Dr Indira Natarajan FRCP, Clinical Director for Stroke, West Midlands SCN & Senate Dr Orsolina.
Nick Banatvala & Pascal Bovet
Non-communicable diseases (NCDs) include:
CVD Prevention Optimal Value Pathway
The GM AHSN AF Landscape Tool: A shared public data platform to promote quality improvements and identify opportunities to prevent AF-related stroke in.
Instructional Objectives:
Tackling High Blood Pressure Through Community Pharmacy
C Wilson, KM Rhodes, RA Payne
QScores: Supporting Vascular Risk Assesessment
Indicators and Outcomes Framework – relevance to patients and commissioners Parul Desai NHS England, London : 7 June 2016.
HEALTH ECONOMICS BASICS
Hypertension November 2016
Delivery of the NHS Health Check by health trainers can improve conversion into uptake of lifestyle service Dr Ifeoma Onyia Public Health Consultant Halton.
Peak oxygen uptake and prevalence of cardiovascular disease risk factors in breast cancer survivors Lahart1, I.M., Metsios1, G.S., Nevill1, A.M., Kitas1,2,
ASSIST CKD: Scaling up an intervention to improve the management of progressive chronic kidney disease.
Lead for the quantitative evaluation
Greater Manchester Health & Social Care Partnership
Background. NCDMod: a microsimulation model exploring the economic impacts of obesity interventions in Australia.
Non-communicable diseases (NCDs) include:
Philip Garner Health Improvement Principal
Local Tobacco Control Profiles The webinar will start at 1pm
Systolic Blood Pressure Intervention Trial (SPRINT)
Local networking sessions
CVD Secondary Prevention plans within Thames Valley
Evaluating the cost-effectiveness of interventions with an impact on ageing P. Breeze, P. Thokala, L. Lafortune, C. Brayne, A. Brennan 07/12/2018.
Innovation & Improvement
by Peter Ueda, Thomas Wai-Chun Lung, Philip Clarke, and Goodarz Danaei
Helen O’Kelly Health service engagement lead, south east
28th November 2016 – First Meeting
Where are we with AF in the West Midlands?
by Peter Ueda, Thomas Wai-Chun Lung, Philip Clarke, and Goodarz Danaei
Managing Age-Related Clinical Issues in Hemophilia
Mpundu MKC MSc Epidemiology and Biostatistics, BSc Nursing, RM, RN
Atrial Fibrillation Local data and data tools: February 2016
High Blood Pressure in General Practice: Variation and Opportunities South Cheshire CCG (v11) 5th March 2019.
Advancing the Science of Transformation in Integrated Primary Care: Informing Options for Scaling-up Innovation   Session 3: Addressing health equity and.
Ambitions and Trajectories
Chapter 1: The Health Benefits of Physical Activity
ASSIST CKD: Scaling up an intervention to improve the management of progressive chronic kidney disease.
Hypertension November 2016
CVD Secondary Prevention plans within Thames Valley
ASSIST CKD: Scaling up an intervention to improve the management of progressive chronic kidney disease.
How will the NHS Long Term Plan work in our community?
Healthy Hearts and Kick It
Dr Timothy Armstrong Coordinator
NICE resources for STPs: MECC
Presentation transcript:

Tools to support development of interventions Soili Larkin & Mohammed Vaqar Public Health England West Midlands

CVD ROI BSOL modelling example Objectives Demonstrate the CVD ROI tool Estimate the potential benefits to an STP area for: Improving detection or management of pre-diabetes and diabetes Improving the usage of key interventions Demonstrate the SHAPE CVD tool The tool allows the interaction of multiple risk factors in a single individual, multiple interventions acting on a risk factor and cross-cutting interventions integrated into the tool CVD ROI BSOL modelling example

Aim of ROI tool To develop an integrated, single platform, local and national ROI tool for CVD prevention in high risk individuals, based on an up-to-date evidence review of interventions for detection or management of high risk conditions Allows the user to explore CVD prevention strategies in patients with one or more of 6 key CVD risk factors, without existing CVD Key exclusions: Primary prevention in the general population, or prevention of subsequent events in people with pre-existing CVD not included in the scope of the tool The tool considers changes in a single risk factor by modelling the impact on a cohort of patients and considering the proportion with other risk factors that could progress to future health events (or complications). The tool then models and accrues associated costs and potential benefits from treatment of all these risk factors. For example, increasing detection of people with previously undiagnosed hypertension will also find with a proportion of these to have undiagnosed diabetes. These ‘incidentally’ diagnosed people with diabetes will then require additional treatments for diabetes as well as hypertension and some may go on to develop complications such as amputations and blindness. How this tool can help decision makers The tool can be used to estimate the effect of strategic changes (e.g. increasing opportunities to diagnose atrial fibrillation across a population), taking account of multiple risk factors and associated changes in service provision (e.g. increasing provision of smoking cessation interventions resulting from incidental identification of smokers). The ability to take account of multiple diagnoses from one programme (and their subsequent effect on treatment costs and benefits) distinguishes this tool from other approaches that just consider individual risk factors individually. The tool can also be used to assess the relative benefits of strategies addressing individual risk factors (and combinations of risk factors) to identify interventions of greatest value. The tool can also be used to consider the impact of the modelled changes on some inequalities (e.g. deprivation and gender). Limitations The tool is not suited for evaluating single interventions for single risk factors without considering wider impacts. In considering ‘incidentally’ diagnosed risk factors the tool estimates a wider range of costs and potentially benefits, but is restricted by the available evidence for considering benefits that can be attributed to the intervention or strategy. ’Incidental’ diagnoses of risk factors and increases in management of one risk factor leading to increased uptake of all associated NICE interventions, the scale of the savings demonstrated from the tool are perhaps smaller that intuitively expected. For example, Improving management of hypertension leads to an increase in the number of people having smoking cessation interventions, but not all benefits from this are modelled such as reduction in lung cancer.   CVD ROI tool

CVD ROI population of interest Six key CVD risk factors included in the ROI population of interest are: High blood pressure; Atrial fibrillation (AF); High cholesterol/high CVD risk; and familial hypercholesterolemia (FH); Diabetes (Type 2 and Type 1); Non-diabetic hyperglycaemia; Chronic kidney disease (CKD Based on the RightCare pathway, these conditions are identified as undiagnosed and/or insufficiently managed The tool allows the interaction of multiple risk factors in a single individual, multiple interventions acting on a risk factor and cross-cutting interventions integrated into the tool CVD ROI tool

CVD ROI tool - overview The underlying model is a microsimulation model The model simulates the population (16 years+), based initially on the Health Survey for England. Baseline characteristics and risks coupled with diagnosis and treatment provide probability of CVD events, diabetes complications, as well as other conditions Population cohort is aged over 20 years. Health trajectories of baseline populations defined by Whitehall II cohort Interventions are applied to individuals that alter risk factors. CVD risk is measured using modified risk scores (QRISK and QStroke). Tool is based on an adaptation of the School for Public Health Research (SPHR) Diabetes Prevention Model NHS management/treatment of risks, as well as expected detection are estimated using administrative data and estimates from a structured evidence review CVD ROI tool

Risk factor progression Model progression Over 20 years Population Update age and metabolic risk status of each individual Risk factor progression Detection Detection and diagnosis of high risk individuals Patients & cost Management Management of high risk individuals Patients & cost The baseline population is aged 20 years Note: management of each high risk condition is defined through optimisation of the subset list of interventions that relate to the management of specific high risk individuals, so if users choose to improve management of a condition, this will impact on the proportion of individuals using certain interventions Disease outcome Progression to disease and mortality events Patients & cost CVD ROI tool

User intervention Each model run by the user simulates the whole population twice firstly under the assumption of current care and; secondly under the assumption of target care (inputted by the tool user) The difference between these simulations then calculated to produce incremental results CVD ROI tool

https://cvd-prevention.shef.ac.uk/

Setting up a model run

Prevalence estimates

Key results

Key results - Costs

Key results - Costs

Key results - Savings

Benefits

Shape tool CVD https://shapeatlas.net/CVD/

Diabetes Prevalence QOF: 2017/18